Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KEPPRA vs MILONTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.
Increases seizure threshold by inhibiting voltage-gated sodium channels and enhancing GABAergic inhibition.
Adjunctive therapy for partial-onset seizures (FDA),Adjunctive therapy for myoclonic seizures in juvenile myoclonic epilepsy (FDA),Adjunctive therapy for primary generalized tonic-clonic seizures (FDA),Off-label: Bipolar disorder, migraine prophylaxis, neuropathic pain, status epilepticus
Adjunctive therapy in the treatment of absence seizures
500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.
Oral, 500 mg twice daily; may increase by 250-500 mg/day every 2-3 days; usual dose 1-2 g/day in 2-3 divided doses; maximum 3 g/day.
6-8 hours in adults; prolonged to 10-18 hours in renal impairment (Cr Cl <30 m L/min); clinical context: dosing interval adjustment required in renal disease.
Terminal elimination half-life is 6–8 hours in adults, longer in children (8–12 hours) and elderly (10–14 hours); clinical context: requires multiple daily dosing to maintain therapeutic levels.
Levetiracetam is not extensively metabolized; ~66% of the dose is excreted unchanged in urine. Metabolism occurs via enzymatic hydrolysis of the acetamide group, independent of cytochrome P450. Major metabolite is the carboxylic acid derivative (ucb L057), which is pharmacologically inactive.
Hepatic via glucuronidation and oxidation; CYP450 involvement minimal.
Renal: 66% unchanged; 27% as inactive metabolite; 0.3% fecal.
Primarily hepatic metabolism and renal excretion; approximately 60% of a dose is excreted in urine as conjugated metabolite (phensuximide glucuronide), with 15% as unchanged drug; 20% eliminated in feces.
<10% bound to plasma proteins (albumin).
Negligible; less than 1% bound to plasma proteins, primarily albumin.
0.5-0.7 L/kg; approximates total body water; clinical meaning: extensive distribution into tissues, including brain.
0.7–0.9 L/kg; clinical meaning: distribution consistent with total body water, indicating minimal tissue binding.
Oral: 100% (immediate-release formulation); IV: 100%.
Oral: nearly 100% (well absorbed from GI tract); no parenteral formulation available.
Cr Cl 50-80 m L/min: 500-1000 mg every 12 hours; Cr Cl 30-49 m L/min: 250-750 mg every 12 hours; Cr Cl <30 m L/min: 250-500 mg every 12 hours; ESRD on dialysis: 500-1000 mg once daily with 250-500 mg supplemental dose after dialysis.
Cr Cl < 50 m L/min: avoid use. No data for milder impairment.
No specific adjustment for hepatic impairment; use caution in severe hepatic impairment.
No specific adjustment recommended; use with caution in severe hepatic impairment.
1 month to <6 months: 7 mg/kg twice daily, titrate to 21 mg/kg twice daily; 6 months to <4 years: 10 mg/kg twice daily, titrate to 25 mg/kg twice daily; 4 to <16 years: 10 mg/kg twice daily, titrate to 30 mg/kg twice daily (maximum 3000 mg/day).
Children 7-12 years: 300 mg orally twice daily initially; increase by 300 mg/day every 2-3 days; usual 600-1200 mg/day in 2-3 divided doses. Infants and children under 7: not recommended.
Start at 250-500 mg twice daily; titrate slowly due to age-related renal function decline.
Start at lower end of dosing range; monitor for sedation and falls; adjust based on renal function.
None
No FDA black box warning.
Behavioral and psychiatric symptoms: psychosis, aggression, suicidal ideation,Somnolence and fatigue, dose-dependent,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hematologic abnormalities: decreased red blood cell, white blood cell, and platelet counts,Acute kidney injury (rare), intercurrent illness may increase risk,Avoid abrupt discontinuation to minimize seizure exacerbation or status epilepticus
May cause drowsiness, dizziness; use caution with other CNS depressants; monitor for blood dyscrasias; withdraw gradually to avoid precipitating seizures.
Hypersensitivity to levetiracetam or any of its components
Hypersensitivity to succinimides; history of porphyria; concurrent use with MAOIs (relative).
No significant food interactions. Levetiracetam absorption is not affected by food. Avoid alcohol as it may increase CNS depression.
No specific food interactions known. Maintain consistent alcohol intake; avoid excessive alcohol as it may lower seizure threshold.
Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester exposure. Risk is dose-dependent and higher with polytherapy. Second and third trimester exposure may be associated with neurodevelopmental impairments.
Phensuximide (Milontin) is an older succinimide anticonvulsant. Human data are limited, but animal studies have shown teratogenic effects. The risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies, is considered increased, especially with first-trimester exposure. Its use in pregnancy is generally avoided unless no safer alternative exists. The risk is highest during the first trimester (organogenesis). Second and third trimester exposure may be associated with growth restriction and neurodevelopmental effects, but data are sparse.
Levetiracetam is excreted into breast milk with an M/P ratio of approximately 1.0. Infant serum levels are about 10-30% of maternal levels. Generally considered compatible with breastfeeding, but monitor infant for drowsiness, poor feeding, and developmental milestones.
Phensuximide is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 0.8. Relative infant dose is estimated at 5-10% of the maternal weight-adjusted dose, which is below the 10% safety threshold; however, individual variability exists. Monitor the infant for drowsiness, poor feeding, and potential hypersensitivity reactions. Breastfeeding is generally considered acceptable with caution, especially if maternal therapy is necessary.
Pregnancy increases levetiracetam clearance by 30-60%, especially in the second and third trimesters. Monitor serum trough concentrations every 1-2 months and increase dose as needed to maintain therapeutic levels. Postpartum, reduce dose to pre-pregnancy levels within the first week.
Pregnancy can increase the clearance of succinimides, potentially reducing serum concentrations. Monitor serum levels frequently (every 4-6 weeks) and adjust dose to maintain therapeutic levels (40-100 mcg/m L) for seizure control. Dose increases may be needed, particularly in the second and third trimesters. Postpartum, doses may need to be reduced to pre-pregnancy levels to avoid toxicity.
Levetiracetam (Keppra) is a broad-spectrum AED with minimal drug interactions. Dosing must be adjusted for renal function (Cr Cl <80 m L/min). Monitor for behavioral changes, especially in pediatric patients. IV formulation can be administered without ECG monitoring. No need for therapeutic drug monitoring; efficacy and tolerability guide dosing.
Milontin (phensuximide) is a succinimide anticonvulsant primarily used for absence seizures. It is a second-line agent after ethosuximide due to higher risk of adverse effects. Monitor for bone marrow suppression, including agranulocytosis and pancytopenia; obtain baseline and periodic CBCs. Hepatitis and nephrosis have been reported; assess liver and renal function periodically. Psychotic episodes may occur, especially in patients with prior psychiatric history. Taper gradually to avoid withdrawal seizures.
Take exactly as prescribed; do not stop suddenly as withdrawal seizures may occur.,Report any unusual mood changes, depression, or aggressive behavior to your doctor.,May cause dizziness or drowsiness; avoid driving until effects are known.,Take with or without food; do not crush extended-release tablets.,Drink plenty of fluids to prevent kidney stones, though not a common side effect.
Take exactly as prescribed; do not stop suddenly as this can cause breakthrough seizures.,Report any signs of infection (fever, sore throat, mouth sores) immediately due to risk of blood disorders.,Notify your doctor if you experience unusual bleeding or bruising, dark urine, or jaundice.,Avoid driving or operating heavy machinery until you know how this medication affects you; it may cause drowsiness or dizziness.,Regular blood tests are required to monitor for side effects.,Use effective contraception if of childbearing age; discuss pregnancy plans with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KEPPRA vs MILONTIN, answered by our medical review team.
KEPPRA is a Antiepileptic that works by Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.. MILONTIN is a Antiepileptic that works by Increases seizure threshold by inhibiting voltage-gated sodium channels and enhancing GABAergic inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KEPPRA and MILONTIN depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KEPPRA is: 500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.. The standard adult dose of MILONTIN is: Oral, 500 mg twice daily; may increase by 250-500 mg/day every 2-3 days; usual dose 1-2 g/day in 2-3 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KEPPRA and MILONTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KEPPRA is classified as Category C. Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester e. MILONTIN is classified as Category C. Phensuximide (Milontin) is an older succinimide anticonvulsant. Human data are limited, but animal studies have shown teratogenic effects. The risk of major congenital malformation. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.